ATE303365T1 - Benzimidazolderivate - Google Patents

Benzimidazolderivate

Info

Publication number
ATE303365T1
ATE303365T1 AT96943331T AT96943331T ATE303365T1 AT E303365 T1 ATE303365 T1 AT E303365T1 AT 96943331 T AT96943331 T AT 96943331T AT 96943331 T AT96943331 T AT 96943331T AT E303365 T1 ATE303365 T1 AT E303365T1
Authority
AT
Austria
Prior art keywords
group
hypertension
carboxyl group
disorders
atherosclerosis
Prior art date
Application number
AT96943331T
Other languages
English (en)
Inventor
Noritsugu Yamasaki
Takafumi Imoto
Yoshiyuki Murai
Takahiro Hiramura
Teruo Oku
Kouzou Sawada
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE303365T1 publication Critical patent/ATE303365T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Insulated Conductors (AREA)
AT96943331T 1995-12-28 1996-12-27 Benzimidazolderivate ATE303365T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34342595 1995-12-28
JP28767696 1996-10-08
PCT/JP1996/003858 WO1997024334A1 (fr) 1995-12-28 1996-12-27 Derives du benzimidazole

Publications (1)

Publication Number Publication Date
ATE303365T1 true ATE303365T1 (de) 2005-09-15

Family

ID=26556834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943331T ATE303365T1 (de) 1995-12-28 1996-12-27 Benzimidazolderivate

Country Status (16)

Country Link
US (2) US6166219A (de)
EP (1) EP0882718B1 (de)
JP (2) JP3063162B2 (de)
CN (1) CN1211238A (de)
AT (1) ATE303365T1 (de)
AU (1) AU722514B2 (de)
BR (1) BR9612434A (de)
DE (1) DE69635135T2 (de)
DK (1) DK0882718T3 (de)
EA (1) EA002357B1 (de)
ES (1) ES2244979T3 (de)
HU (1) HUP9900625A3 (de)
IL (1) IL124969A (de)
NZ (1) NZ324834A (de)
TR (1) TR199801249T2 (de)
WO (1) WO1997024334A1 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
EP1000932B9 (de) * 1997-06-27 2005-12-28 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
KR20010014183A (ko) 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
ATE273996T1 (de) * 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
BR9909440A (pt) * 1998-04-06 2000-12-26 Fujisawa Pharmaceutical Co Derivados de indol
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
EP1132087A4 (de) * 1998-11-13 2002-06-26 Fujisawa Pharmaceutical Co Heilmittel gegen polyzystisches-eierstock-syndrom
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
CZ20011981A3 (cs) 1998-12-04 2002-01-16 Fujisawa Pharmaceutical Co., Ltd. Sulfonamidové sloučeniny
CZ20012338A3 (cs) 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2000039099A1 (fr) * 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Derives de benzimidazole
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
AU4055400A (en) * 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
FR2792635B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique
JP2001169268A (ja) 1999-12-14 2001-06-22 Sony Corp 情報提供システム、送信サーバ、情報端末装置、オーサリング装置及び情報提供方法
GB9914255D0 (en) * 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
WO2001005770A1 (en) * 1999-07-21 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Benzimidazolone derivatives and their use as phosphodiesterase inhibitors
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
CN1167680C (zh) 1999-12-27 2004-09-22 日本烟草产业株式会社 稠环化合物及其药物用途
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
ATE343388T1 (de) * 2000-04-19 2006-11-15 Lilly Icos Llc Pde-v hemmer zur behandlung von morbus parkinson
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
US20020169166A1 (en) * 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
KR100863147B1 (ko) * 2001-03-09 2008-10-13 아보트 러보러터리즈 벤즈이미다졸 및 이를 포함하는 성 기능장애 치료용 약제학적 조성물
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
EP1442042A1 (de) 2001-11-09 2004-08-04 Schering Corporation Polyzyklisches guaninderivat phosphodiesterase-v-inhibitoren
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
US7132547B2 (en) * 2001-12-28 2006-11-07 Takeda Pharmaceutical Company Limited Preventives/remedies for urinary disturbance
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301698D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
KR20060054410A (ko) * 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 플라비비리다에에 대한 2고리 이미다졸 유도체
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP4355917B2 (ja) * 2003-10-29 2009-11-04 信越化学工業株式会社 含窒素有機化合物、レジスト材料及びパターン形成方法
TW200533336A (en) * 2004-03-02 2005-10-16 Fujisawa Pharmaceutical Co Concomitant drugs
CA2560928A1 (en) * 2004-03-29 2005-10-06 Sankyo Company Limited Therapeutic agent for diabetes containing insulin resistance improving agent
US7915443B2 (en) * 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
CN101133036B (zh) * 2004-09-30 2010-10-13 詹森药业有限公司 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物
SG156636A1 (en) * 2004-10-12 2009-11-26 Decode Genetics Ehf Carboxylic acid peri -substituted bicyclics for occlusive artery disease
DE602005026553D1 (de) * 2004-10-12 2011-04-07 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
WO2006045478A1 (en) * 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
DE602005011844D1 (de) * 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
EP1676573A1 (de) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Zusammensetzung enthaltend eine 2,5-Dihydroxybenzolsulfonsäure-Verbindung, einen Kalium Kanal Modulator und einen Phosphodiesterase 5 Inhibitor
AU2006204917A1 (en) * 2005-01-14 2006-07-20 Smithkline Beecham Corporation Indole derivatives for treating viral infections
BRPI0613447A2 (pt) * 2005-07-12 2016-11-16 Daiichi Sankyo Co Ltd composição farmacêutica, usos de um agonista de ppargama e de um agente biguanida, e, kit para evitar ocorrência de efeitos colaterais adversos devido à ação de um agente biguanida no tratamento do diabetes
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1917251B1 (de) 2005-08-21 2013-04-03 Abbott GmbH & Co. KG 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
WO2007093507A1 (en) * 2006-02-13 2007-08-23 F. Hoffmann-La Roche Ag Heterobicyclic sulfonamide derivatives for the treatment of diabetes
JP2009536918A (ja) * 2006-03-06 2009-10-22 ファイザー株式会社 スルホニルベンゾイミダゾール誘導体
TW200745049A (en) * 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
WO2007137042A2 (en) 2006-05-16 2007-11-29 Decode Genetics, Ehf. Process for preparing 7- (acryl0yl) -ind0les
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8501957B2 (en) * 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
US20100317706A1 (en) * 2009-04-30 2010-12-16 Bumham Institute For Medical Research HNF4alpha MODULATORS AND METHODS OF USE
CA2769508C (en) * 2009-07-30 2020-01-07 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with benzimidazole derivative agonists of ppargamma
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
TWI458714B (zh) * 2009-12-10 2014-11-01 Univ China Medical 苯并咪唑化合物及其用途
EP2397471A1 (de) * 2010-06-16 2011-12-21 China Medical University Benzimidazolverbindungen und deren Verwendung
JP5782234B2 (ja) * 2010-06-16 2015-09-24 チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ ベンゾイミダゾール化合物およびその使用
EP2638014B1 (de) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylierte tetrahydrochinoline und verwandte bizyklische verbindungen zur inhibition der ror-gamma aktivität und zur behandlung von krankheiten
WO2012102405A1 (ja) * 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
WO2012174312A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
EP2847198B1 (de) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridinsulfonamid und verwandte verbindungen zur verwendung als ror-gamma-agonisten und behandlung von krankheiten
CA2871514C (en) 2012-05-08 2020-08-25 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ror.gamma.activity and the treatment of disease
CN102702006A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种3-氨基-2-硝基苯甲酸乙酯的制备方法
EP2858983B1 (de) * 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha-modulierende benzimidazole
US9512119B2 (en) 2012-07-27 2016-12-06 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
CN102827084A (zh) * 2012-08-21 2012-12-19 江苏恒祥化工有限责任公司 一种2-(二氯甲基)苯并咪唑的制备方法
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
MX371017B (es) 2014-02-03 2020-01-13 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3209641A4 (de) 2014-05-05 2018-06-06 Lycera Corporation Benzolsulfonamid und verwandte verbindungen zur verwendung als ror-agonisten und behandlung von erkrankungen
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
CN104860919B (zh) * 2015-03-26 2017-11-10 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
EP3368535B1 (de) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl-substituierte benzoesäuren als ror-gamma-t-hemmer und verwendungen davon
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
RU2018120308A (ru) 2015-12-11 2019-12-03 Тейдзин Фарма Лимитед Производное аминоазола
TW202220968A (zh) * 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
CN107311933B (zh) * 2017-06-28 2020-12-22 中国人民解放军军事医学科学院毒物药物研究所 一类苯并咪唑衍生物，及其制备方法和用途
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN108947911B (zh) * 2018-07-03 2022-02-22 中山大学 一种具有抗乙肝病毒活性和抗菌活性的苯并咪唑类化合物及其合成方法和应用
CN111116485B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双（4-氨基苄基）-2-三氟甲基-1h-苯并咪唑的制备方法
CN111116484B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双（4-氨基苄基）-1,2二甲基-苯并咪唑的制备方法
CN111057011B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双（4-氨基苄基）-1-甲基-2-苯基苯并咪唑的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE676196C (de) * 1936-08-21 1939-05-30 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Imidazolverbindungen
US3152142A (en) * 1962-05-24 1964-10-06 Dow Chemical Co Benzimidazole compounds
US4243813A (en) 1974-07-01 1981-01-06 Eli Lilly And Company Substituted 1-sulfonylbenzimidazoles
FR2291749A1 (fr) * 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
JPS51133267A (en) * 1975-05-08 1976-11-18 Lilly Co Eli Substituted 11sulphonyl benzimidazole
US4179505A (en) * 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4243806A (en) * 1979-06-13 1981-01-06 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
GB2053215B (en) * 1979-06-25 1983-04-07 May & Baker Ltd Benzimidazole derivatives
JPS625966A (ja) * 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
JPH03218362A (ja) * 1988-12-22 1991-09-25 Yamanouchi Pharmaceut Co Ltd ４，５，６，７―テトラヒドロベンズイミダゾール誘導体及びそれを含有する医薬
AU7759591A (en) * 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
RU1836357C (ru) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
DE4224133A1 (de) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5602127A (en) * 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
DE4237557A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
JPH0853424A (ja) * 1994-08-11 1996-02-27 Kureha Chem Ind Co Ltd ベンズイミダゾールスルホン酸アミド誘導体
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JPH11154208A (ja) 1997-11-21 1999-06-08 Mitsubishi Electric Corp Ｉｃカード及びその製造方法

Also Published As

Publication number Publication date
NZ324834A (en) 2001-11-30
BR9612434A (pt) 1999-12-28
ES2244979T3 (es) 2005-12-16
EP0882718A4 (de) 1999-08-04
DE69635135T2 (de) 2006-07-06
CN1211238A (zh) 1999-03-17
DK0882718T3 (da) 2005-12-12
JP2000159749A (ja) 2000-06-13
HUP9900625A2 (hu) 1999-06-28
EP0882718B1 (de) 2005-08-31
EA002357B1 (ru) 2002-04-25
DE69635135D1 (en) 2005-10-06
US6352985B1 (en) 2002-03-05
AU722514B2 (en) 2000-08-03
US6166219A (en) 2000-12-26
TR199801249T2 (xx) 1998-10-21
JP3063162B2 (ja) 2000-07-12
EP0882718A1 (de) 1998-12-09
IL124969A0 (en) 1999-01-26
IL124969A (en) 2002-09-12
WO1997024334A1 (fr) 1997-07-10
HUP9900625A3 (en) 2003-04-28
EA199800609A1 (ru) 1999-02-25
AU1209597A (en) 1997-07-28

Similar Documents

Publication Publication Date Title
DK0882718T3 (da) Benzimidazolderivater
EP1000932A4 (de) Derivate mit einem aromatischen ring
Sunkel et al. Synthesis of 3-[(2, 3-dihydro-1, 1, 3-trioxo-1, 2-benzisothiazol-2-yl) alkyl] 1, 4-dihydropyridine-3, 5-dicarboxylate derivatives as calcium channel modulators
OA11089A (en) Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as ampa-receptor antagonists
EP0539509A1 (de) 4-alkylimidazolderivate.
CA2241186A1 (en) Benzimidazole derivatives
JP4422335B2 (ja) グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸ｎ−アリールアミド
WO1991001724A1 (en) Renal-selective prodrugs for the treatment of hypertension
KR20010085852A (ko) 2,3-이치환 피리딘 유도체, 그의 제조방법, 그를 함유하는의약 조성물, 및 그의 제조용 중간체
JP3483160B2 (ja) ピリドピリミジンジオン類、その製造方法およびそれを含有する薬剤
JPH07267954A (ja) 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１ノナン−化合物、その製法及び抗不整脈剤
JPS6143183A (ja) 新規２ｈ‐１‐ベンゾピラン‐２‐オン誘導体、その製法およびこれを含有する抗アレルギー性疾患治療剤
JP2004067510A (ja) 新規イミダゾール誘導体
JP2948076B2 (ja) 新規チアゾリジンジオン化合物
US5356922A (en) Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
Sircar et al. Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1, 4-dihydro-6-methyl-2-[(phenylsulfonyl) methyl]-4-aryl-3-pyridinecarboxylate and analogs. Synthesis and structure-activity relationships
WO1999003858A9 (fr) Derives purine et leur application medicinale
JP3024781B2 (ja) ロダニン誘導体
WO1992014730A1 (en) Thiazolidine-2,4-dione derivative, salt thereof, and production thereof
JPH03141257A (ja) ジヒドロピリジン誘導体
US4628057A (en) Tetrahydro-β-carboline derivatives and treatment of liver diseases
JPH01157955A (ja) 新規複素環誘導体およびその製造法
JPH07101941A (ja) ２−［２−（置換アミノ）ベンジルチオ］−５，６， ７，８−テトラヒドロ−４（３ｈ）−キナゾリノン誘 導体
JP3228792B2 (ja) 新規環状アミノフェニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤
DK153395B (da) Analogifremgangsmaade til fremstilling af basisk substiuerede 5-sulfamoyl-anthranilsyrer eller deres fysiologisk taalelige salte

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties